Meeting HHS’ minimum requirements for daily and weekly exercise reduced breast cancer recurrence and mortality among patients with high-risk breast cancer undergoing chemotherapy. This benefit was even seen in patients who had not met these requirements before their diagnosis.
Even meeting HHS’s minimum requirements for daily and weekly exercise reduced breast cancer recurrence and mortality among patients with high-risk disease undergoing chemotherapy. This benefit was even seen in patients who had not met these requirements before their diagnosis, according to research from Roswell Park Comprehensive Cancer Center in Buffalo, New York, published in Journal of the National Cancer Institute.
The patient population they investigated consisted of 1340 individuals currently enrolled in the Diet, Exercise, Lifestyles and Cancer Prognosis (DELCaP) study, a questionnaire distributed as part of a larger trial from SWOG. Their levels of physical activity, according to HHS’ Physical Activity Guidelines for Americans, and the resulting effects were measured at 4 time points:
Four levels of physical activity were also used to classify patients, according to weekly MET hours:
Overall, large reductions in disease recurrence and mortality were seen among the patients who met the RPA guidelines both before and in the year following enrollment. These hazard ratios (HRs) were 0.59 (95% CI, 0.42-0.82) and 0.51 (95% CI, 0.34-0.77), respectively. These numbers only got better at the 2-year mark, coming in at 0.45 (95% CI, 0.31-0.65) and 0.32 (95% CI, 0.19-0.52).
When looking at amounts of RPA each week, the patients classified as low active (HR, 0.41; 95% CI, 0.24-0.68), moderate active (HR, 0.42; 95% CI, 0.23-0.76), and high active (HR, 0.31; 95% CI, 0.18-0.53) saw the most gains in mortality improvement.
Overall, the most patients (75.1%) were active at the 2-year mark. In addition, any level of consistent RPA throughout the study translated to 19% and 22% drops in disease recurrence and mortality, respectively. Even larger statistically significant gains were seen following time-dependent analyses. The mortality rate fell by 63% among patients who exercised on a regular basis versus those who did not and by 60% if they met the minimum requirements for RPA.
“Taken collectively, these findings have important implications in the clinical oncology setting because they suggest that a cancer diagnosis may serve as an impetus for increasing physical activity in some patients, and among these patients, beginning an exercise program after treatment resulted in a survival advantage,” stated Rikki Cannioto, PhD, ED, assistant professor of oncology, Department of Cancer Prevention and Control, Roswell. “These observations coincide with previous findings from our group showing that lower levels of regular, weekly activity were associated with a significant survival advantage.”
Due to the self-reported nature of the study, the study authors express caution about the possibility of recall errors on the part of the patients, which could mean data misclassification and skewed results.
Reference
Cannioto RA, Hutson A, Dighe S, et al. Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival [published online April 2, 2020]. J Natl Cancer Inst. doi: 10.1093/jnci/djaa046.
Racial Inequities in Guideline-Adherent Breast Cancer Care and Timely Treatment
November 19th 2024Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
Advancing Breast Cancer Care With HER2-Targeted Therapies
October 10th 2024In this interview from our Institute for Value-Based Medicine® event in Boston, we speak with Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, on the clinical significance and cost implications of HER2 in the breast cancer space.
Read More
Managing Germline Mutations in Hereditary Breast Cancer Risk
October 7th 2024Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.
Read More